{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T01:10:07Z","timestamp":1770685807314,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T00:00:00Z","timestamp":1507075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T00:00:00Z","timestamp":1507075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"crossref","award":["AG AG016573"],"award-info":[{"award-number":["AG AG016573"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"crossref","award":["AG016570"],"award-info":[{"award-number":["AG016570"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13195-017-0311-5","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T12:03:48Z","timestamp":1507118628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Attitudes toward clinical trials across the Alzheimer\u2019s disease spectrum"],"prefix":"10.1186","volume":"9","author":[{"given":"Michelle M.","family":"Nu\u00f1o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Gillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kulwant K.","family":"Dosanjh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Brook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Elashoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Ringman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Grill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,4]]},"reference":[{"key":"311_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","volume":"12","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, Middleton LT. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016;12:60\u20134.","journal-title":"Alzheimers Dement."},{"key":"311_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1126\/scitranslmed.3002609","volume":"3","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack Jr CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3:111\u201333.","journal-title":"Sci Transl Med."},{"key":"311_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement."},{"key":"311_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O\u2019Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734\u201346.","journal-title":"Lancet Neurol."},{"key":"311_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","volume":"9","author":"B Dubois","year":"2010","unstructured":"Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O\u2019Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer\u2019s disease: a new lexicon. Lancet Neurol. 2010;9:1118\u201327.","journal-title":"Lancet Neurol."},{"key":"311_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack Jr CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement."},{"key":"311_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/jama.2014.1361","volume":"311","author":"B Kasenda","year":"2014","unstructured":"Kasenda B, von Elm E, You J, Blumle A, Tomonaga Y, Saccilotto R, Amstutz A, Bengough T, Meerpohl JJ, Stegert M, Tikkinen KA, Neumann I, Carrasco-Labra A, Faulhaber M, Mulla SM, Mertz D, Akl EA, Bassler D, Busse JW, Ferreira-Gonzalez I, Lamontagne F, Nordmann A, Gloy V, Raatz H, Moja L, Rosenthal R, Ebrahim S, Schandelmaier S, Xin S, Vandvik PO, Johnston BC, Walter MA, Burnand B, Schwenkglenks M, Hemkens LG, Bucher HC, Guyatt GH, Briel M. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014;311:1045\u201351.","journal-title":"JAMA"},{"key":"311_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/alzrt58","volume":"2","author":"JD Grill","year":"2010","unstructured":"Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer\u2019s disease clinical trials. Alzheimers Res Ther. 2010;2:34.","journal-title":"Alzheimers Res Ther."},{"key":"311_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/(SICI)1099-1166(200004)15:4<325::AID-GPS117>3.0.CO;2-9","volume":"15","author":"P Elad","year":"2000","unstructured":"Elad P, Treves TA, Drory M, Verchovsky R, Klimovitsky S, Ben-Laish S, Yaron S, Ginzburg K, Korczyn AD. Demented patients\u2019 participation in a clinical trial: factors affecting the caregivers\u2019 decision. Int J Geriatr Psychiatry. 2000;15:325\u201330.","journal-title":"Int J Geriatr Psychiatry."},{"key":"311_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.56.6.789","volume":"56","author":"JH Karlawish","year":"2001","unstructured":"Karlawish JH, Casarett D, Klocinski J, Sankar P. How do AD patients and their caregivers decide whether to enroll in a clinical trial? Neurology. 2001;56:789\u201392.","journal-title":"Neurology."},{"key":"311_CR11","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1046\/j.1532-5415.2002.50615.x","volume":"50","author":"JH Karlawish","year":"2002","unstructured":"Karlawish JH, Casarett DJ, James BD. Alzheimer\u2019s disease patients\u2019 and caregivers\u2019 capacity, competency, and reasons to enroll in an early-phase Alzheimer\u2019s disease clinical trial. J Am Geriatr Soc. 2002;50:2019\u201324.","journal-title":"J Am Geriatr Soc."},{"issue":"Suppl 2","key":"311_CR12","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1097\/00002093-200200002-00009","volume":"16","author":"JT Olin","year":"2002","unstructured":"Olin JT, Dagerman KS, Fox LS, Bowers B, Schneider LS. Increasing ethnic minority participation in Alzheimer disease research. Alzheimer Dis Assoc Disord. 2002;16 Suppl 2:S82\u201385.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"311_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/geront\/43.1.45","volume":"43","author":"D Gallagher-Thompson","year":"2003","unstructured":"Gallagher-Thompson D, Solano N, Coon D, Arean P. Recruitment and retention of Latino dementia family caregivers in intervention research: issues to face, lessons to learn. Gerontologist. 2003;43:45\u201351.","journal-title":"Gerontologist."},{"key":"311_CR14","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1212\/01.wnl.0000336652.05779.ea","volume":"71","author":"J Karlawish","year":"2008","unstructured":"Karlawish J, Cary MS, Rubright J, Tenhave T. How redesigning AD clinical trials might increase study partners\u2019 willingness to participate. Neurology. 2008;71:1883\u20138.","journal-title":"Neurology."},{"key":"311_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/01634370903361847","volume":"53","author":"CR Gelman","year":"2010","unstructured":"Gelman CR. Learning from recruitment challenges: barriers to diagnosis, treatment, and research participation for Latinos with symptoms of Alzheimer\u2019s disease. J Gerontol Soc Work. 2010;53:94\u2013113.","journal-title":"J Gerontol Soc Work."},{"key":"311_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1377\/hlthaff.2013.1314","volume":"33","author":"JL Watson","year":"2014","unstructured":"Watson JL, Ryan L, Silverberg N, Cahan V, Bernard MA. Obstacles and opportunities in Alzheimer\u2019s clinical trial recruitment. Health Aff (Millwood). 2014;33:574\u20139.","journal-title":"Health Aff (Millwood)"},{"key":"311_CR17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/j.1532-5415.2008.01752.x","volume":"56","author":"AL Jefferson","year":"2008","unstructured":"Jefferson AL, Lambe S, Moser DJ, Byerly LK, Ozonoff A, Karlawish JH. Decisional capacity for research participation in individuals with mild cognitive impairment. J Am Geriatr Soc. 2008;56:1236\u201343.","journal-title":"J Am Geriatr Soc."},{"key":"311_CR18","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/JGP.0b013e318252e5cb","volume":"20","author":"AL Jefferson","year":"2012","unstructured":"Jefferson AL, Carmona H, Gifford KA, Lambe S, Byerly LK, Cantwell NG, Tripodis Y, Karlawish J. Clinical research risk assessment among individuals with mild cognitive impairment. Am J Geriatr Psychiatry. 2012;20:878\u201386.","journal-title":"Am J Geriatr Psychiatry."},{"key":"311_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/gps.3958","volume":"29","author":"V Lawrence","year":"2014","unstructured":"Lawrence V, Pickett J, Ballard C, Murray J. Patient and carer views on participating in clinical trials for prodromal Alzheimer\u2019s disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2014;29:22\u201331.","journal-title":"Int J Geriatr Psychiatry."},{"key":"311_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jalz.2012.03.001","volume":"9","author":"JD Grill","year":"2013","unstructured":"Grill JD, Karlawish J, Elashoff D, Vickrey BG. Risk disclosure and preclinical Alzheimer\u2019s disease clinical trial enrollment. Alzheimers Dement. 2013;9:356\u20139. e351.","journal-title":"Alzheimers Dement"},{"key":"311_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neurobiolaging.2015.11.007","volume":"39","author":"JD Grill","year":"2016","unstructured":"Grill JD, Zhou Y, Elashoff D, Karlawish J. Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer\u2019s disease clinical trials. Neurobiol Aging. 2016;39:147\u201353.","journal-title":"Neurobiol Aging."},{"key":"311_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37\u201346.","journal-title":"Educ Psychol Meas."},{"key":"311_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1037\/h0026256","volume":"70","author":"J Cohen","year":"1968","unstructured":"Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968;70:213\u201320.","journal-title":"Psychol Bull."},{"key":"311_CR24","doi-asserted-by":"crossref","DOI":"10.1002\/9781119013563","volume-title":"Statistical analysis with missing data","author":"RJA Little","year":"2002","unstructured":"Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. Hoboken, NJ: Wiley-Interscience; 2002.","edition":"2"},{"key":"311_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159\u201374.","journal-title":"Biometrics."},{"key":"311_CR26","first-page":"205","volume":"56","author":"S Bardach","year":"2016","unstructured":"Bardach S, Holmes S, Jicha G. Motivators for Alzheimer\u2019s disease clinical trial participation. Gerontologist. 2016;56:205\u20136.","journal-title":"Gerontologist."},{"key":"311_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/WAD.0000000000000149","volume":"30","author":"M Leach","year":"2016","unstructured":"Leach M, Ziaian T, Francis A, Agnew T. Recruiting dementia caregivers into clinical trials lessons learnt from the Australian Transcendent Trial. Alzheimer Dis Assoc Disord. 2016;30:338\u201344.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"311_CR28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1212\/WNL.0b013e31827debfe","volume":"80","author":"JD Grill","year":"2013","unstructured":"Grill JD, Raman R, Ernstrom K, Aisen P, Karlawish J. Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology. 2013;80:282\u20138.","journal-title":"Neurology."},{"key":"311_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/WAD.0000000000000047","volume":"29","author":"MS Cary","year":"2015","unstructured":"Cary MS, Rubright JD, Grill JD, Karlawish J. Why are spousal caregivers more prevalent than nonspousal caregivers as study partners in AD dementia clinical trials? Alzheimer Dis Assoc Disord. 2015;29:70\u20134.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"311_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000339361","volume":"33","author":"JD Grill","year":"2012","unstructured":"Grill JD, Monsell S, Karlawish J. Are patients whose study partners are spouses more likely to be eligible for Alzheimer\u2019s disease clinical trials? Dement Geriatr Cogn Disord. 2012;33:334\u201340.","journal-title":"Dement Geriatr Cogn Disord."},{"key":"311_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1017\/S104161020700511X","volume":"19","author":"WE Faison","year":"2007","unstructured":"Faison WE, Schultz SK, Aerssens J, Alvidrez J, Anand R, Farrer LA, Jarvik L, Manly J, McRae T, Murphy Jr GM, Olin JT, Regier D, Sano M, Mintzer JE. Potential ethnic modifiers in the assessment and treatment of Alzheimer\u2019s disease: challenges for the future. Int Psychogeriatr. 2007;19:539\u201358.","journal-title":"Int Psychogeriatr."},{"key":"311_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-015-0112-7","volume":"7","author":"K Harkins","year":"2015","unstructured":"Harkins K, Sankar P, Sperling R, Grill JD, Green RC, Johnson KA, Healy M, Karlawish J. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7:26.","journal-title":"Alzheimers Res Ther."},{"key":"311_CR33","first-page":"114","volume":"3","author":"J Cummings","year":"2016","unstructured":"Cummings J, Aisen P, Barton R, Bork J, Doody R, Dwyer J, Egan JC, Feldman H, Lappin D, Truyen L, Salloway S, Sperling R, Vradenburg G. Re-engineering Alzheimer clinical trials: Global Alzheimer\u2019s Platform Network. J Prev Alzheimers Dis. 2016;3:114\u201320.","journal-title":"J Prev Alzheimers Dis."},{"key":"311_CR34","first-page":"68","volume":"3","author":"PT Aisen","year":"2016","unstructured":"Aisen PT, Andrieu J, Boada S, Doody M, Nosheny R. Registries and cohorts to accelerate early phase Alzheimer\u2019s trials: a report from the EU\/US Clinical Trials in Alzheimer\u2019s Disease Task Force. J Prev Alz Dis. 2016;3:68\u201374.","journal-title":"J Prev Alz Dis."},{"key":"311_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2215-0366(15)00454-X","volume":"3","author":"CW Ritchie","year":"2016","unstructured":"Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S, European Prevention of Alzheimer\u2019s Dementia (EPAD) Consortium. Development of interventions for the secondary prevention of Alzheimer\u2019s dementia: the European Prevention of Alzheimer\u2019s Dementia (EPAD) project. Lancet Psychiatry. 2016;3:179\u201386.","journal-title":"Lancet Psychiatry"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0311-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-017-0311-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0311-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T11:28:47Z","timestamp":1589542127000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-017-0311-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,4]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1186\/s13195-017-0311-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,4]]},"assertion":[{"value":"9 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The UCLA Institutional Review Board approved the study. Study participants signed and returned an informed consent document confirming their willingness to participate and to have their responses linked to their other data collected as part of the UCLA ADRC longitudinal study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JDG has served as an investigator on studies sponsored by Eli Lilly & Company, Biogen Idec, and the Alzheimer\u2019s Disease Cooperative Study. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"81"}}